United States · Bill · HR
H.R. 3348 (115th)
Adding Middle East Respiratory Syndrome to the FDA Priority Review Voucher Program Act
Introduced
20 July 2017
Last action
—
Status
Referred to the House Committee on Energy and Commerce.
Sponsors
—
Subjects
Discovery layer
Source updated
11 August 2025
Summary
Adding Middle East Respiratory Syndrome to the FDA Priority Review Voucher Program Act This bill amends the Federal Food, Drug, and Cosmetic Act to include Middle East respiratory syndrome under the priority review voucher program for tropical diseases, which awards a voucher to the sponsor of a new drug or biological product that is approved to prevent or treat a tropical disease. (A voucher entitles the holder to have a future new drug or biological product application acted upon by the Food and Drug Administration within six months.)
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
3 official files
Introduced in House (text)
Introduced in House (text)
Introduced in House · EN · 20 July 2017
Introduced in House (PDF)
Introduced in House · EN · 20 July 2017
Introduced in House
summary · EN · 20 July 2017
Sponsors
No sponsors or actors listed by the source.
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/bill/115th-congress/house-bill/3348
- Open data entity: https://api.congress.gov/v3/bill/115/hr/3348